Results 191 to 200 of about 372,366 (307)

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr   +18 more
wiley   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo   +22 more
wiley   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel   +12 more
wiley   +1 more source

Asymmetry Analysis in Rodent Cerebral Ischemia Models

open access: green, 2008
Sheena Xin Liu   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy